GBA Presents: House of Gummy-!

In looking for year 24' ideas one group will be the comeback kids stocks that have not done well. And in Bumble we have just that.

Another sub sector will be plays pinging off the weight loss drugs/ society.
And Bumble scores there as well. Thin people like to get laid.

It's expensive & I do not know how the Co makes money.
If anyone has used Bumble.. chip in on the experience.

Is This a swipe right sik?> Is that this stk? The swiping?


YEAR 24' IDEA->BMBL Bumble Inc.

$14.34-0.02(-0.14%)1:39 PM 12/13/23
 
vanzandt said:
So check it out... right at 10:03 ET is when ACAD jumped, apparently on the news they won some patent lawsuit... but right before it jumped, like the minute before, someone buys 270 of the $23 calls for $0.70.

Nothing like making $130,000 off of $19K eh?

How'd they do that? A Bloomberg terminal? I wonder if it was even a human. It had to be though, I don't think an algo could do that. Unless it was setup to monitor incoming order flow. Hmph. Must be nice.
More...
I’ve been playing the strange flow on CCCC, I made a few coins off the $2.50 calls and $5c. Holding some for $6.
 
VAN - do we officially close House Of Gummy for the fourth time at the new year and then start a YEAR 24 thread?

might be a good idea. Otherwise House Of Gummy will continue on and on and on...

Incyte Stock Is the S&P 500’s Top Performer. Here’s Why It’s Surging.

Dec 12, 2023, 12:43 pm EST


INCY

best trading session in more than six years.


The stock rose 8.6% to $61.97 on Tuesday, putting Incyte shares on pace for their largest increase since Aug. 30, 2017, when they gained 11%, according to Dow Jones Market Data. It was the top performer in the S&P 500

The two days of gains likely stem from data announced at the American Society of Hematology annual meeting that began Dec. 9 and runs through Tuesday.

In a press release Sunday, Incyte and Syndax Pharmaceuticals
shared full results of a phase 2 trial of antibody axatilimab in adult and pediatric patients with refractory chronic graft-versus-host disease (GVHD) who had received at least two prior lines of systemic therapy. GVHD is defined by the National Library of Medicine as a systemic disease that occurs when transplanted tissue’s immune cells view the person’s own tissues as foreign and attack those cells.



The two companies said the trial met the primary endpoint across all cohorts receiving the antibody. Based on the results and a pending agreement from the Food and Drug Administration, they expect to submit a biologics license application to the FDA by the end of the year.
 
TrailerParkTed said:
I’ve been playing the strange flow on CCCC, I made a few coins off the $2.50 calls and $5c. Holding some for $6.
More...



BLBD Ted! Options flying. Jan 19 $25's -> +38% // Jan $30's + 50% <-- Only .30 cents :wtf:

Dec 15 $22.50's + 142%

Weeeeeeeeeeeeeeeeeeeeeeeeee :cool:

vol up

BLBD-------------VOL Alert***********1,016,611

Avg. Volume-->316,758
 
You must log in or register to reply here.
Back
Top